Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1999 1
2015 2
2018 1
2024 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Metastatic Unresectable Basal Cell Carcinoma"
Page 1
Japanese Dermatological Association guidelines: Outlines of Japanese clinical guidelines for basal cell carcinoma 2021.
Hoashi T, Ishikawa M, Uehara J, Oashi K, Maeda S, Kato J, Saruta H, Shichinohe R, Ohashi R, Nakamura Y, Koga H, Sugaya M; Basal Cell Carcinoma Guidelines Committee of the Japanese Skin Cancer Society. Hoashi T, et al. J Dermatol. 2024 Apr;51(4):e90-e105. doi: 10.1111/1346-8138.16944. Epub 2024 Jan 24. J Dermatol. 2024. PMID: 38264942
To summarize the current therapies for skin cancers, the Japanese Skin Cancer Society issued the first guidelines for skin cancers, including melanoma, squamous cell carcinoma, basal cell carcinoma (BCC), and extramammary Paget's disease, in 200 …
To summarize the current therapies for skin cancers, the Japanese Skin Cancer Society issued the first guidelines for skin cancers, includin …
Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus.
Peris K, Licitra L, Ascierto PA, Corvò R, Simonacci M, Picciotto F, Gualdi G, Pellacani G, Santoro A. Peris K, et al. Future Oncol. 2015;11(4):703-12. doi: 10.2217/fon.14.281. Future Oncol. 2015. PMID: 25686123 Review.
Basal cell carcinoma (BCC) is the most common skin cancer worldwide. Most occur on the head and neck, where cosmetic and functional outcomes are critical. ...Surgery is the treatment of choice for the majority of high-risk lesions. Aggressive, recurrent or …
Basal cell carcinoma (BCC) is the most common skin cancer worldwide. Most occur on the head and neck, where cosmetic an …
Vismodegib induces significant clinical response in locally advanced trichoblastic carcinoma.
Lepesant P, Crinquette M, Alkeraye S, Mirabel X, Dziwniel V, Cribier B, Mortier L. Lepesant P, et al. Br J Dermatol. 2015 Oct;173(4):1059-62. doi: 10.1111/bjd.13919. Epub 2015 Aug 27. Br J Dermatol. 2015. PMID: 25998864
Patients with advanced basal cell carcinoma due to local extension or metastatic disease were previously at a therapeutic impasse. ...We report a patient with trichoblastic carcinoma, initially diagnosed as basal cell carcinoma …
Patients with advanced basal cell carcinoma due to local extension or metastatic disease were previously at a th …
Unresectable primary facial cutaneous carcinoma.
Whitaker DC. Whitaker DC. J Dermatol Surg Oncol. 1992 Feb;18(2):125-9. doi: 10.1111/j.1524-4725.1992.tb02443.x. J Dermatol Surg Oncol. 1992. PMID: 1537949
Even with high cure rates, thousands of patients will require secondary treatment. Some nonmelanoma skin cancers are very aggressive and may not be resectable following single treatment failure. ...
Even with high cure rates, thousands of patients will require secondary treatment. Some nonmelanoma skin cancers are very aggressive …
The clinical course of lung carcinoma in patients with chronic lymphocytic leukemia.
Parekh K, Rusch V, Kris M. Parekh K, et al. Cancer. 1999 Nov 1;86(9):1720-3. Cancer. 1999. PMID: 10547544
Histologically, the lung carcinomas included 6 squamous cell carcinomas, 19 nonsquamous carcinomas, and 1 small cell carcinoma. Ten patients (38%) had a third malignancy; these malignancies included melanoma, basal cell carcinoma, larynge …
Histologically, the lung carcinomas included 6 squamous cell carcinomas, 19 nonsquamous carcinomas, and 1 small cell carcin …
Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
Gray HJ, Bell-McGuinn K, Fleming GF, Cristea M, Xiong H, Sullivan D, Luo Y, McKee MD, Munasinghe W, Martin LP. Gray HJ, et al. Gynecol Oncol. 2018 Mar;148(3):507-514. doi: 10.1016/j.ygyno.2017.12.029. Epub 2018 Jan 17. Gynecol Oncol. 2018. PMID: 29352572 Clinical Trial.
METHODS: In this phase I study, patients with metastatic or unresectable solid tumors and 2 prior chemotherapy regimens received veliparib combined with carboplatin area under the curve (AUC) 4 on day 1 and gemcitabine 800mg/m(2) on days 1 and 8 of a 21-day cycle fo …
METHODS: In this phase I study, patients with metastatic or unresectable solid tumors and 2 prior chemotherapy regimens receiv …